Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers - Full Text View

Sponsor:	National Cancer Institute (NCI)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00001164

Purpose

It is proposed that patients with skin disease due to presumed immunologic, genetic or viral-induced abnormalities, patients with neurological degenerations, and normal controls be evaluated with various in vitro studies of immunologic, genetic, and virologic function. This is to include studies of peripheral blood (cells and serum) as well as studies of skin obtained with a biopsy instrument. In addition, studies of gastrointestinal function will be performed where appropriate.

Condition
Healthy Muscular Dystrophy Retinal Degeneration Skin Diseases Virus Diseases

Study Type:	Observational
Official Title:	Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers

Resource links provided by NLM:

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Muscular Dystrophy Skin Conditions

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Study Start Date:	July 1978
Estimated Study Completion Date:	June 2000

Detailed Description:

It is proposed that patients with skin disease due to presumed immunologic, genetic or viral-induced abnormalities, patients with neurological degenerations, and normal controls be evaluated with various in vitro studies of immunologic, genetic, and virologic function. This is to include studies of peripheral blood (cells and serum) as well as studies of skin obtained with a biopsy instrument. In addition, studies of gastrointestinal function will be performed where appropriate.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Patients with skin diseases of presumed genetic, immunologic, or virologic origin are eligible.

Patients with neurological degenerations are eligible, including patients with inflammatory, neoplastic and viral skin diseases and also heterozygous carriers of such inherited diseases.

Volunteers without skin diseases are eligible, except children.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001164

Locations

United States, Maryland
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Cancer Institute (NCI)

More Information

Publications:

Kraemer KH, Coon HG, Petinga RA, Barrett SF, Rahe AE, Robbins JH. Genetic heterogeneity in xeroderma pigmentosum: complementation groups and their relationship to DNA repair rates. Proc Natl Acad Sci U S A. 1975 Jan;72(1):59-63.

Yaoita H, Katz SI. Immunoelectronmicroscopic localization of IgA in skin of patients with dermatitis herpetiformis. J Invest Dermatol. 1976 Oct;67(4):502-6.

Study ID Numbers:	780099, 78-C-0099
Study First Received:	November 3, 1999
Last Updated:	March 4, 2008
ClinicalTrials.gov Identifier:	NCT00001164 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Genetic Evaluation
Immunologic Evaluations
Inflammatory Skin Disease
Muscular Dystrophies

Neoplastic Skin Diseases
Neuronal Degenerations
Retinal Degenerations
Viral Diseases

Additional relevant MeSH terms:

Virus Diseases
Muscular Dystrophies
Muscular Diseases
Genetic Diseases, Inborn
Neuromuscular Diseases
Musculoskeletal Diseases

Muscular Disorders, Atrophic
Skin Diseases
Eye Diseases
Nervous System Diseases
Retinal Degeneration
Retinal Diseases

ClinicalTrials.gov processed this record on November 27, 2009